Stavudine in first-line antiretroviral regimens in resource-limited settings: Time for a better solution

HIV Therapy

Volumn 3, Issue 2, 2009, Pages 109-111

  Bartlett, John A ^a,b   Maro, Venance P ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b KILIMANJARO CHRISTIAN MEDICAL UNIVERSITY COLLEGE   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GENERIC DRUG; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL PLUS ZIDOVUDINE; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ABNORMAL BODY BUILD; ANEMIA; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CLINICAL RESEARCH; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; FANCONI RENOTUBULAR SYNDROME; FATTY LIVER; GLOMERULUS FILTRATION RATE; HEALTH CARE ACCESS; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; LACTIC ACIDOSIS; LIPOATROPHY; PANCREATITIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; RESOURCE MANAGEMENT; SIDE EFFECT; SURVIVAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 67149118157     PISSN: 17584310     EISSN: None     Source Type: Journal    
DOI: 10.2217/17584310.3.2.109     Document Type: Editorial

References (22)

1. Weidle P, Malamba S, Mwebaze R et al.: Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival and drug resistance. Lancet 360, 34-40 (2002). (Pubitemid 34756490)
2. + count betwen 351-500 cells/mm3 is associated with improved survival. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 25-28 October 2008 (Abstract H-869b).
3. Steinbrook R: Closing the affordability gap for drugs in low-income countries. N. Engl. J. Med. 357, 1996-1999 (2007).
4. Gallant J, Staszewski S, Pozniak A et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive adults: a 3-year randomized trial. J. Am. Med. Assoc. 292, 191-201 (2004). (Pubitemid 38917996)
5. Zerit® , package insert. Bristol Myers Squibb, New York, NY, USA.
6. Forna F, Liechty C, Solberg P et al.: Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J. Acquir. Immune Def. Syndr. 44, 456-462 (2007). (Pubitemid 46555382)
7. Hill A, Ruxrungtham K, Hanvanich M et al.: Systematic review of clinical trials evaluating low doses of stavudine antiretroviral treatment. Expert Opin Pharmacother. 8, 679-688 (2007). (Pubitemid 46547020)
8. Van Griensven J, Mushi T, Ubarijoro S, Denaeyer L: Prevalence of lipodystrophy after 1 year of WHO first-line ART in Kigali, Rwanda. Presented at: The 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5-8 February 2006.
9. Vergel N: Impact of body changes on the quality of life of HIV-positive treatment-experienced patients - an online community-based survey. Antivir. Ther. 13(Suppl. 4), A73 (2008).
10. Rankin W, Brennan S, Schell E, Laviwa J, Rankin S: The stigma of being HIV-positive in Africa. PLoS Med. 2(8), e247 (2005).
11. Duran S, Saves M, Spire B et al.: Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 15, 2441-2444 (2001). (Pubitemid 34014613)
12. Ammassari A, Murri R, Pezzotti P et al.: Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J. Acquir. Immune Def. Syndr. 28, 445-449 (2001). (Pubitemid 34033195)
13. Gallant J, DeJesus E, Arribas J et al.: Tenofovir DF, emtricitabine, and efavirenz versus zidovudine, lamivudine and efavirenz for HIV. N. Engl. J. Med. 354, 251-260 (2006). (Pubitemid 43113030)
14. Sax P, Tierney C, Collier A et al.: ACTG 5202, shorter time to virologic failure (VF) with abacavir/lamivudine (ABC/3TC) than tenofovir/emtricitabine (TDF/FTC) as part of combination therapy in treatment-naive subjects with screening HIV RNA greater than 100,000 c/ml. Presented at: The XVII International AIDS Conference. Mexico City, Mexico, 3-8 August 2008.
15. Viread® , package insert. Gilead Sciences, Foster City, CA, USA.
16. DART Virology Group and Trial Team: Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 20, 1391-1399 (2006).
17. Reid AJC, DART Team: Glomerular dysfunction and associated risk factors following initiation of ART in Africa: a subanalysis in the DART trial. Presented at: The XVI International AIDS Conference. Toronto, Canada, 13-18 August 2006.
18. Rosen S, Long L, Fox M, Sanne I: Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. J. Acquir. Immune Def. Synr. 48, 334-344 (2008).
19. UNAIDS: Report on the global AIDS epidemic (2008). www.unaids.org/en/ KnowledgeCentre/HIVData/GlobalReport/2008/2008-Global-report.asp
20. Medecins sans frontieres. www.accessmed-msf.org
21. Addendum to 2006 WHO guidelines on antiretroviral therapy HIV infection for adults and adolescents. www.who.int/entity/hiv/art/ARTadultsaddendum.pdf
22. DHHS guidelines for treatment-naive patients. www.aidsinfo.nih.gov/ contentfiles/adultandadolescentgl.pdf